Long-Term Risk of Major Adverse Cardiac Events in Atrial Fibrillation Patients on Direct Oral Anticoagulants

Mayo Clinic Proceedings

Volumn 96, Issue 3, 2021, Pages 658-665

  Pastori, Daniele ^a   Menichelli, Danilo ^a   Del Sole, Francesco ^a   Pignatelli, Pasquale ^a,b   Violi, Francesco ^a,b   Casciaro, Marco Antonio ^c   Saliola, Mirella ^c   Carnevale, Roberto ^c   De Russis, Marco ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Mediterranea Cardiocentro   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGE; AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK REDUCTION; VERY ELDERLY; MEDICATION COMPLIANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; FEMALE; HEART FAILURE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RIVAROXABAN;

EID: 85097152166     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2020.06.057     Document Type: Article

References (24)

1. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:38 (2016), 2893–2962.
2. Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
3. Go, A.S., Singer, D.E., Toh, S., et al. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 167:12 (2017), 845–854.
4. Soliman, E.Z., Safford, M.M., Muntner, P., et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 174:1 (2014), 107–114.
5. Violi, F., Soliman, E.Z., Pignatelli, P., Pastori, D., Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc, 5(5), 2016, e003347.
6. Lip, G.Y., Lane, D.A., Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?. Am J Med 123:9 (2010), 785–789.
7. Pastori, D., Pignatelli, P., Angelico, F., et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 147:6 (2015), 1644–1650.
8. Rasmussen, L.H., Larsen, T.B., Graungaard, T., Skjoth, F., Lip, G.Y., Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ, 345, 2012, e7097.
9. Stolk, L.M., de Vries, F., Ebbelaar, C., et al. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 83:8 (2017), 1835–1843.
10. Uchino, K., Hernandez, A.V., Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:5 (2012), 397–402.
11. Pratt, N.L., Ramsay, E., Kalisch Ellett, L.M., et al. Comparative effectiveness and safety of low-strength and high-strength direct oral anticoagulants compared with warfarin: a sequential cohort study. BMJ Open, 9(5), 2019, e026486.
12. Lee, C.J.Y., Gerds, T.A., Carlson, N., et al. Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 72:1 (2018), 17–26.
13. Darwiche, W., Bejan-Angoulvant, T., Angoulvant, D., Babuty, D., Fauchier, L., Risk of myocardial infarction and death in patients with atrial fibrillation treated with dabigatran or vitamin K antagonists. Meta-analysis of observational analyses. Thromb Haemost 116:6 (2016), 1150–1158.
14. Loffredo, L., Perri, L., Violi, F., Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials. Int J Cardiol 178 (2015), 8–9.
15. Ntaios, G., Papavasileiou, V., Makaritsis, K., Vemmos, K., Michel, P., Lip, G.Y.H., Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke 48:9 (2017), 2494–2503.
16. Pastori, D., Nocella, C., Farcomeni, A., et al. Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation. J Am Coll Cardiol 70:12 (2017), 1455–1462.
17. Steffel, J., Verhamme, P., Potpara, T.S., et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:16 (2018), 1330–1393.
18. Pastori, D., Farcomeni, A., Saliola, M., et al. Temporal trends of time in therapeutic range and incidence of cardiovascular events in patients with non-valvular atrial fibrillation. Eur J Intern Med 54 (2018), 34–39.
19. Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 60:16 (2012), 1581–1598.
20. Piccini, J.P., Hellkamp, A.S., Lokhnygina, Y., et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc, 3(2), 2014, e000521.
21. Wallentin, L., Lopes, R.D., Hanna, M., et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127:22 (2013), 2166–2176.
22. Wallentin, L., Yusuf, S., Ezekowitz, M.D., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:9745 (2010), 975–983.
23. Pignatelli, P., Pastori, D., Bartimoccia, S., et al. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacol Res 113:Pt A (2016), 484–489.
24. Al-Tamimi, M., Grigoriadis, G., Tran, H., et al. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 117:14 (2011), 3912–3920.